Trial Profile

Mechanistic Investigation of Therapies for Down Syndrome Regression Disorder

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Immune globulin (Primary) ; Lorazepam (Primary) ; Tofacitinib (Primary)
Indications Down syndrome
Focus Adverse reactions

Most Recent Events

25 Jan 2023 Status changed from not yet recruiting to recruiting, according to a Childrens Hospital Los Angeles media release.
25 Jan 2023 According to a Childrens Hospital Los Angeles media release, Children's Hospital Los Angeles (CHLA) has launched this trial and trial is funded by a five-year, 5.3 million dollar grant from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute for Child Health and Human Development.
23 Dec 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com